Nonconvulsive status epilepticus or acute repetitive seizures Intravenous lacosamide status epilepticus acute repetitive seizures epilepsy
Conditions
Interventions
A prospective interventional study was conducted in children under 18 years of age with NCSE or ARS who either had contraindication to,
or were refractory to first-
line AEDs,
and received intravenous lacosamide.
Experimental Drug
Sponsors
Phramongkutklao hospital
Eligibility
Sex/Gender
All
Age
No minimum to 18 Years
Inclusion criteria
Inclusion criteria: 1.patients with status epilepticus and/or acute repetitive seizures aged less than 18 years 2.patients who had uncontrollable seizures after first-line antiepileptic drug therapies 3.patients with a contraindication to first-line antiepileptic drugs (allergy to drugs, comorbidity, drug interaction, risk of side effects).
Exclusion criteria
Exclusion criteria: 1.Lacosamide use within 1 month 2.Allergic to lacosamide 3.Pregnancy patients 4.Underlying disease of cardiac AV block
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| seizure outcome during i.v. LCM treatment at 24 hours and 1 week Comparison between frequency of seizure baseline 1 month and % of seizure reduction after i.v. LCM | — |
Secondary
| Measure | Time frame |
|---|---|
| adverse effect of Lacosamide during i.v. LCM treatment at 24 hours and 1 week observation | — |
Countries
Thailand
Contacts
Public ContactPiradee Suwanpakdee
Phramongkutklao hospital
Outcome results
None listed